In the last trading session, 1.17 million shares of the Travere Therapeutics Inc (NASDAQ:TVTX) were traded, and its beta was 0.68. Most recently the company’s share price was $17.39, and it changed around -$0.33 or -1.86% from the last close, which brings the market valuation of the company to $1.51B. TVTX currently trades at a discount to its 52-week high of $20.33, offering almost -16.91% off that amount. The share price’s 52-week low was $5.12, which indicates that the current value has risen by an impressive 70.56% since then. We note from Travere Therapeutics Inc’s average daily trading volume that its 10-day average is 1.52 million shares, with the 3-month average coming to 1.87 million.
Travere Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.31. If we narrow it down even further, the data shows that 0 out of 19 analysts rate the stock as a Sell; another 6 rate it as Overweight. Among the rest, 3 recommended TVTX as a Hold, whereas 10 deemed it a Buy, and 0 rated it as Underweight. Travere Therapeutics Inc is expected to report earnings per share of -0.4 for the current quarter.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Travere Therapeutics Inc (NASDAQ:TVTX) trade information
Instantly TVTX has showed a red trend with a performance of -1.86% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 19.51 on recent trading dayincreased the stock’s daily price by 10.87%. The company’s shares are currently up 93.44% year-to-date, but still down -8.62% over the last five days. On the other hand, Travere Therapeutics Inc (NASDAQ:TVTX) is -2.69% down in the 30-day period. We can see from the shorts that 7.99 million shares have been sold at a short interest cover period of 3.92 day(s).
The consensus price target as assigned by Wall Street analysts is $21.5, which translates to bulls needing to increase their stock price by 19.12% from its current value. Analyst projections state that TVTX is forecast to be at a low of $12 and a high of $33.
Travere Therapeutics Inc (TVTX) estimates and forecasts
Travere Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 181.85 percent over the past six months and at a 22.49% annual growth rate that is well above the industry average of 17.50%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 57.60% in revenue this quarter, and will report an increase of 77.05% in the next quarter. The year-over-year growth rate is expected to be 58.78%, up from the previous year.
Consensus estimates provided by 13 financial analysts predict the company will bring in an average of 70.89M in revenue for the current quarter. 5 analysts expect Travere Therapeutics Inc to make 71.82M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 45.06M and 41.37M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 57.33%. Forecasts for the next quarter put sales growth at 73.59%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -12.34%.
TVTX Dividends
Travere Therapeutics Inc’s next quarterly earnings report is expected to be released in December.
ARMISTICE CAPITAL, LLC, with 9.6774% or 7.5 million shares worth $61.65 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
